PX1 Research has announced the launch of a new line of sublingual peptide strips manufactured in the United States, designed specifically for needle-free research applications. The product line includes formulations of retatrutide, tirzepatide, and BPC-157, marking a significant departure from traditional injectable peptide delivery methods. This move is expected to address logistical and procedural challenges in research settings where non-invasive administration is preferred or required.
The strips are produced under current Good Manufacturing Practice (cGMP) protocols, ensuring stringent quality control throughout the manufacturing process. Each batch undergoes High-Performance Liquid Chromatography (HPLC) purity verification, with results confirming 99% or greater purity across all formulations. Additionally, each product is accompanied by a Certificate of Analysis, providing researchers with documented evidence of batch composition before use. The domestic manufacturing approach emphasizes supply chain transparency, which is crucial for institutional researchers who require detailed documentation trails.
Among the available formulations, dissolving retatrutide strips have drawn particular attention due to the compound's role in ongoing metabolic and weight regulation research. Tirzepatide and BPC-157 are also included, extending coverage to compounds associated with glucose regulation and tissue repair research, respectively. The sublingual delivery format allows the strip to dissolve under the tongue, enabling absorption without needles or syringes. This is particularly beneficial for research environments where non-invasive administration is a design requirement, whether due to protocol specifications, institutional review considerations, or participant-facing study designs.
The full product line is accessible through PX1 Research, with specific information on dissolving retatrutide strips available directly on the product page. The company has positioned these sublingual peptide strips specifically for academic and institutional research contexts. They are not intended for clinical, therapeutic, or human consumption use. Instead, the product addresses demand from researchers who require compounds delivered in a format compatible with non-invasive study designs, where traditional needle-based administration would introduce procedural variables or ethical complications.
The inclusion of BPC-157 alongside GLP-1 receptor agonist-class compounds such as retatrutide and tirzepatide signals that the line is intended to serve a range of research disciplines. Each compound presents distinct molecular properties, and the sublingual strip format has been adapted to accommodate the specific stability and absorption characteristics relevant to each formulation. This development represents a notable advancement in research peptide delivery, potentially streamlining protocols and expanding the possibilities for non-invasive studies.
